Platelet Counting Patents: Who Leads, Where the Gaps Are 2026
- 48.3% concentration. The top 5 of 85 ranked assignees account for 143 of 296 records in scope — near half the field sits with a handful of filers.
- Filing has cooled from its peak. Activity peaked at 30 records in 2023; the 2021-to-2024 span shows a -100% swing, though 2025-2026 counts are still filling in as publication catches up.
- G01N dominates, A61M barely registers. Material analysis & testing claims sit in 53.0% of records versus 6.4% for body-fluid devices — the assay side is crowded, the instrumentation side much less so.
Filing growth compares 2021 (12 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 296 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families addressing platelet counting and the sources of interference that distort it — giant platelets, clumping, sample age effects, and the assay standardization work needed to make a count trustworthy at a transfusion-trigger threshold. The search spans 296 published records filed or published between 2015 and mid-2026, drawing on both the diagnostic instrumentation side (fluorescence platelet channels, electric and magnetic measurement) and the therapeutic and biomarker side that shares claim language with it.
Because a single filing often carries claims across measurement, therapeutic composition and diagnostic marker categories at once, the technology composition below is read by class share of the full record set rather than as a strict partition. Family-level counting is used throughout to avoid inflating the picture with continuation filings or multi-jurisdiction duplicates of the same invention.
Filing trend and technology composition
Two views of the same 296-record set: how filing activity has moved year over year, and which IPC subclasses carry the claim language.
A filing peak already behind it
Annual filings rose from 9 in 2017 to a peak of 30 in 2023, then the 2021-to-2024 comparison shows a -100% change. Treat 2025 and 2026 as incomplete rather than as evidence of a real decline — publication typically lags filing by around 18 months, so the most recent two years will keep filling in.
Assay and marker classes crowd out device claims
G01N (material analysis & testing) appears in 53.0% of the 296 records and A61K (medicinal preparations) in 42.9%, reflecting how much of this landscape is shared with biomarker and therapeutic filings rather than pure counting hardware. C12Q and A61P each sit near 29%, C12N and C07K in the mid-teens, and A61M (body-fluid devices) and G01R (electric & magnetic measurement) trail at 6.4% and 3.4% respectively — the instrumentation end of the field is comparatively open.
Shares are the percentage of the 296 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Platelet Counting and Interference with Eureka
This page is one run against one query. Ask Eureka your own question about platelet counting and interference and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the corpus
Diagnosis of abnormal blood conditions based on polymorphisms in the glycoprotein VI gene
Methods of diagnosis of abnormal blood conditions associated with an increased risk of bleeding are described. Subjects homozygous or heterozygous for the GPVIb allele are considered to be at increased risk of bleeding. Kits for carrying out the methods of diagnosis, and use of the methods and kits for determining the GPVI allelotype of subjects in need of surgery, with a low platelet count, with an acquired bleeding disorder, on blood thinning drugs, or of blood donors is also described.Filed by Ouwehand, Willem — published 2005-11-17 as US20050255470A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2002089657A2 | Diagnostic markers of acute coronary syndromes and methods of use thereof | 343 |
| 2 | US20110212090A1 | Combinatorial Analysis and Repair | 329 |
| 3 | US20030199000A1 | Diagnostic markers of stroke and cerebral injury and methods of use thereof | 230 |
| 4 | US20040209307A1 | Diagnostic markers of stroke and cerebral injury and methods of use thereof | 201 |
| 5 | US20030109420A1 | Diagnostic markers of acute coronary syndrome and methods of use thereof | 180 |
| 6 | WO2010009735A2 | Combinatorial analysis and repair | 173 |
| 7 | US6025201A | Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets… | 160 |
| 8 | US5817519A | Automated method and device for identifying and quantifying platelets and for determining platelet activation… | 160 |
| 9 | US7929121B2 | Method and apparatus for detecting and counting platelets individually and in aggregate clumps | 139 |
| 10 | US6403381B1 | Inhibition of coagulation in blood and blood products | 123 |
Citation counts favor older filings that have had more time to accumulate references — read them as a signal of influence within this searched corpus, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three read-outs from the concentration, timing and classification figures above.
Half the field sits with a handful of assignees
The leader alone holds 43 records; the fifth-place assignee holds 16 and the tenth holds 12. That gradient — a strong leader, a mid-pack of five-to-teens, then a long tail across 85 ranked companies — means freedom-to-operate work should focus first on the top 5's actual claim scope rather than treating the field as fragmented.
Peak filing has passed, but read 2025-2026 with caution
Filings climbed from 9 in 2017 to 30 in 2023. The 2021-to-2024 window shows a -100% change, but because publication lags filing by roughly 18 months, the most recent one to two years understate real activity rather than proving a slowdown.
Device claims are comparatively light
G01N and A61K each cover well over 40% of records, but A61M (devices for body fluids) sits at only 6.4% and G01R (electric & magnetic measurement) at 3.4%. Assay chemistry and marker/therapeutic claims are dense; the instrumentation layer that turns a count into a usable transfusion-trigger reading is thinner.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to platelet counting and interference, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Haemostatix Ltd | GOODALL ALISON HELENA | 4 |
| Haemostatix Ltd | TAYLOR SARAH MARGARET | 3 |
| Alere San Diego Inc | VALKIRS GUNARS E | 3 |
| Alere San Diego Inc | DAHLEN JEFFREY R | 3 |
| Alere San Diego Inc | BUECHLER KENNETH F | 3 |
| Alliance Pharma Corp | WEERS JEFFREY | 3 |
| Alliance Pharma Corp | KLEIN DAVID | 3 |
| Alliance Pharma Corp | JOHNSON CINDY | 3 |
Only 10 co-assignee pairs appear across the corpus, and the strongest pairs link a single company to individual named inventors rather than to another corporate assignee — this field shows little cross-company joint filing.
Who holds the claim space
The ranked leaders account for most of the volume, but recent-year filing counts suggest the leaders themselves have gone quiet even as their historical portfolios remain in force.
One assignee holds the largest single share
The top-ranked company in the 85-assignee ranking holds 43 of the 296 records — more than double the fifth-place count of 16. Its portfolio is the first stop for any clearance search in this space.
A compact second tier, then a long tail
Between fifth place (16 records) and tenth place (12 records) the drop-off is gradual, but beyond the top 10 — which together hold 70.9% of all 296 records — the remaining 75 ranked companies each hold small, often single-digit portfolios.
Recent-year filing has gone quiet across named leaders
Several of the historically largest assignees, including Hemostatix, Alere San Diego, T2 Biosystems, Abbott Point of Care and Bayer, show zero filings in the latest tracked year; one smaller filer shows a single filing at 0% year-on-year. This likely reflects publication lag as much as any real pullback.
| Assignee | Recent year | YoY |
|---|---|---|
| Alexion Pharmaceuticals | 1 | 0% |
| Haemostatix Ltd | 0 | — |
| Alere San Diego Inc | 0 | — |
| T2 Biosystems Inc | 0 | — |
| Abbott Point of Care Inc | 0 | — |
| Bayer Corp | 0 | — |
| Geron Corp | 0 | -100% |
| Beckman Coulter Inc | 0 | — |
Where to take this analysis
The landscape figures point to next steps rather than conclusions — each one is a narrower question this dataset can help answer.
Check freedom-to-operate against the top 5
With 48.3% of records held by five assignees, a targeted claim-scope review of those five portfolios will cover close to half the field before broadening the search.
Explore assignee portfolios in EurekaWatch the instrumentation side for entrants
A61M and G01R sit well below the assay-heavy classes — new point-of-care and sizing-hardware filings would be the earliest sign of the field's underclaimed corner opening up.
Track new filings in EurekaConfirm 2025-2026 counts before drawing conclusions
Publication lag means the apparent drop after 2023 is partly an artifact of the data cut-off; revisit the trend once more of the 2025-2026 filing year has published.
Set a filing alert in EurekaCommon questions about this landscape
The dataset ranks 85 assignees across 296 records, with a clear leader holding 43 records — more than double the fifth-place holder's 16. The top 5 assignees together account for 48.3% of all records in scope, and the top 10 account for 70.9%, so concentration is high at the very top even though the full ranking runs to 85 companies. Beyond the top 10, portfolios thin out quickly into single-digit counts, which is typical of a field with a few dominant instrument and diagnostics makers plus many smaller biomarker-focused filers.
Filing rose from 9 records in 2017 to a peak of 30 in 2023, and the 2021-to-2024 comparison shows a -100% change over that span. However, patent publication typically lags actual filing by around 18 months, so the 2025 and 2026 counts in any dataset with a mid-2026 cut-off are still incomplete. The honest read is that the field peaked in 2023 and the most recent years cannot yet be judged as rising or falling.
G01N (material analysis and testing) appears in 53.0% of the 296 records and A61K (medicinal preparations) in 42.9%, making assay chemistry and marker/therapeutic claims the densest part of the landscape. A61M (devices for body fluids) at 6.4% and G01R (electric and magnetic measurement) at 3.4% are comparatively open, suggesting the physical instrumentation and point-of-care device layer carries fewer competing claims than the underlying assay science.
Interference sources like giant platelets, clumping and sample age appear in the search scope alongside core counting claims, and the technology composition shows this material sits mostly within the G01N and C12Q classes rather than as a distinct device category. That means most interference-correction claims are framed as measurement or assay method improvements rather than as standalone hardware, which is worth checking before assuming a hardware fix is unclaimed territory.
US20050255470A1 covers diagnosis of abnormal blood conditions based on GPVI gene polymorphisms, tying genetic allelotype to bleeding risk assessment in subjects with low platelet counts or on blood-thinning drugs. It is a representative record in this corpus rather than the single most-cited one, but its claim scope over genotype-based bleeding-risk diagnosis is a useful marker for anyone whose product touches genetic risk stratification alongside a platelet count reading. Citation volume in this field skews toward older biomarker patents, so influence here should be read as historical significance, not as a signal that the claims are still the tightest blocking point today.
Research Platelet Counting and Interference in depth with Eureka
Go past this page: query the whole platelet counting and interference corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.